Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is rate of acute graft-versus-host disease II-IV measured at day
+365according to conventional criteria (Przepiorka et al. 1995) in patients with high risk
non-Hodgkin lymphoma B subjects with Allogeneic Stem Cell Transplant
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea